title: Effect of antenatal tocolysis on neonatal outcomes.
abstract: OBJECTIVE
  Detail adverse neonatal effects in pregnancies treated with indomethacin (I), magnesium sulfate (M) or nifedipine (N).
  
  
  METHODS
  Women in acute preterm labor with cervical dilatation 1-6 cm were randomized to receive one of three first-line tocolytic drugs.
  
  
  RESULTS
  There were 317 neonates (I = 103, M = 95, N = 119) whose mothers were treated with tocolytic therapy. There was no difference in gestational age at randomization (average 28.6 weeks' gestation) or at delivery (31.6 weeks' gestation, p = 0.551), birth weight (p = 0.871) or ventilator days (p = 0.089) between the three groups. Neonatal morbidity was not different between the three groups; respiratory distress syndrome (p = 0.086), patent ductus arteriosus (p = 0.592), sepsis (p = 0.590), necrotizing enterocolitis (p = 0.770), intraventricular hemorrhage (p = 0.669) and periventricular leukomalacia (p = 0.124).
  
  
  CONCLUSIONS
  There were no statistically significant differences between the three tocolytics as far as composite neonatal morbidity or mortality was concerned.
authors.affiliation: Department of Obstetrics and Gynecology, The Mount Sinai Medical Center, New York City, NY, USA.
authors.forename: Chad K
authors.initials: CK
authors.lastname: Klauser
authors.forename: Christian M
authors.initials: CM
authors.lastname: Briery
authors.forename: Sharon D
authors.initials: SD
authors.lastname: Keiser
authors.forename: Rick W
authors.initials: RW
authors.lastname: Martin
authors.forename: Mary A
authors.initials: MA
authors.lastname: Kosek
authors.forename: John C
authors.initials: JC
authors.lastname: Morrison
mesh_terms: D005260:Female; D005865:Gestational Age; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000139:chemically induced / Q000453:epidemiology; D008278:Magnesium Sulfate / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D009017:Morbidity; D009543:Nifedipine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D007752:Obstetric Labor, Premature / Q000188:drug therapy / Q000517:prevention & control; D011247:Pregnancy; D011256:Pregnancy Outcome / Q000453:epidemiology*; D011297:Prenatal Exposure Delayed Effects / Q000139:chemically induced / Q000453:epidemiology*; D015145:Tocolysis / Q000009:adverse effects / Q000379:methods / Q000706:statistics & numerical data; D015149:Tocolytic Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D015149:Tocolytic Agents; D008278:Magnesium Sulfate; D009543:Nifedipine; D007213:Indomethacin